Overview

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

Status:
Terminated

Trial end date:
2019-02-13

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if sapacitabine given in combination with 2 standard drugs (cyclophosphamide and rituximab) can help to control CLL and SLL. The safety of this drug combination will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Cyclacel Pharmaceuticals, Inc.
National Cancer Institute (NCI)

Treatments:

Cyclophosphamide
Rituximab
Sapacitabine